Physician profile
Raven Thacker
NPI 1003673559
$1,295.95
in general payments reported to CMS, 2019-2025
16 companies · $623 in 2025
The $623 reported for 2025 was more than what 80% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $673 · 2025: $623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,295.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $202.79 | 2024-2025 | Jaypirca |
| Sobi, INC | $186.97 | 2024-2025 | |
| Incyte Corporation | $165.47 | 2024-2025 | Jakafi, Niktimvo |
| Novartis Pharmaceuticals Corporation | $106.60 | 2024-2025 | |
| Abbvie INC. | $92.72 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $65.49 | 2025 | Calquence |
| Celgene Corporation | $64.57 | 2025 | Reblozyl |
| Syndax Pharmaceuticals, INC. | $63.74 | 2025 | |
| Merck Sharp & Dohme LLC | $58.98 | 2025 | |
| Pharmaessentia USA Corporation | $57.60 | 2024 | Besremi |
| Daiichi Sankyo INC. | $54.31 | 2024 | Vanflyta |
| Beigene USA, INC. | $52.98 | 2024 | Brukinsa |
| Taiho Oncology, INC. | $35.03 | 2025 | |
| Astellas Pharma US INC | $31.10 | 2025 | Cresemba |
| Glaxosmithkline, LLC. | $30.06 | 2024 | Ojjaara |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $27.54 | 2024 | Imbruvica |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raven Thacker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.